Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ravasio

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Advances in Therapy|January 22, 2017
Comment on "Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate"Roberto Ravasio
Clinical Drug Investigation|October 10, 2009
Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world settingMario Guidotti, Roberto Ravasio
Clinical Drug Investigation|December 18, 2007
Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphomaFelicetto Ferrara, Roberto Ravasio
Global & Regional Health Technology Assessment|January 11, 2023
Giovanni Di Minno, Roberto Ravasio
Clinicoeconomics and Outcomes Research : CEOR|August 3, 2017
Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexateMaurizio Benucci, Roberto Ravasio, Arianna Damiani
Current Opinion in Genetics & Development|May 7, 2016
Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotypeRoberto Ravasio, Elena Ceccacci, Saverio Minucci
Global & Regional Health Technology Assessment|January 16, 2023
Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still's DiseaseRoberto Ravasio, Roberto Giacomelli, Stefano Bianchi
Epidemiologia E Psichiatria Sociale|March 22, 2003
[Services and recruited patients]Marianna Cavazza, Graziella Civenti, Roberto Ravasio
Global & Regional Health Technology Assessment|January 11, 2023
Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi
Italian Journal of Pediatrics|June 4, 2009
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infantsGaetano Chirico, Roberto Ravasio, Urbano Sbarigia
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Advances in Therapy|January 22, 2017
Comment on "Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate"Roberto Ravasio
Clinical Drug Investigation|October 10, 2009
Clinical and economic comparison of frovatriptan versus other oral triptans in the treatment of acute migraine in the real-world settingMario Guidotti, Roberto Ravasio
Clinical Drug Investigation|December 18, 2007
Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphomaFelicetto Ferrara, Roberto Ravasio
Global & Regional Health Technology Assessment|January 11, 2023
Giovanni Di Minno, Roberto Ravasio
Clinicoeconomics and Outcomes Research : CEOR|August 3, 2017
Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexateMaurizio Benucci, Roberto Ravasio, Arianna Damiani
Current Opinion in Genetics & Development|May 7, 2016
Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotypeRoberto Ravasio, Elena Ceccacci, Saverio Minucci
Global & Regional Health Technology Assessment|January 16, 2023
Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still's DiseaseRoberto Ravasio, Roberto Giacomelli, Stefano Bianchi
Epidemiologia E Psichiatria Sociale|March 22, 2003
[Services and recruited patients]Marianna Cavazza, Graziella Civenti, Roberto Ravasio
Global & Regional Health Technology Assessment|January 11, 2023
Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi
Italian Journal of Pediatrics|June 4, 2009
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infantsGaetano Chirico, Roberto Ravasio, Urbano Sbarigia
Pageof 4